WeissR., “Nanotech Raises Worker-Safety Questions,”Washington Post, April 8, 2006, at A1.
5.
The Royal Society & The Royal Academy of Engineering, Report, Nanoscience and Nanotechnologies: Opportunities and Uncertainties – Summary and Recommendations (2004), available at <http://www.nanotec.org.uk/finalreport.htm> (last visited September 13, 2006).
6.
RocoM.C. and BainbridgeW. S., eds., National Science Foundation, Report, Converging Technologies for Improving Human Performance: Nanotechnology, Biotechnology, Information Technology and Cognitive Science (2002), available at <http://www.wtec.org/ConvergingTechnologies/Report/NBIC_report.pdf.> (last visited September 24, 2006).
BaumR., “Nanotechnology: Drexler and Smalley Make the Case for and against ‘Molecular Assemblers’,”Chemical & Engineering News, December 1, 2003, at 37. Available at <http://pubs.acs.org/cen/coverstory/8148/8148counterpoint.html> (last visited September 13, 2006).
9.
RocoM. C. and BainbridgeW. S., eds., Societal Implications of Nanoscience and Nanotechnology (Boston: Kluwer Academic Publishers, 2001): at 4.
See Lux Research, Press Release, Nanotechnology in $32 Billion Worth of Products; Global Funding for Nanotech R&D Reaches $9.6 Billion (May 8, 2006). Available at <http://www.luxresearchinc.com/press/RELEASE_TNR4.pdf> (last visited September 14, 2006).
RobichaudC. O., “Relative Risk Analysis of Several Manufactured Nanomaterials: An Insurance Industry Context,”Environmental Science & Technology39 (2005): 8985–8993, at 8985.
KloeppelJ. E., “Selective Coatings Create Biological Sensors from Carbon Nanotubes,” University of Illinois at Urbana-Champlain website, available at <http://www.news.uiuc.edu/NEWS/04/1213strano.html> (last visited September 14, 2006).
37.
Supra note 17, at 19.
38.
Id.
39.
Id.
40.
Id.
41.
Id.
42.
NelA., “Toxic Potential of Materials at the Nanolevel,”Science311, no. 5761 (2006): 622–627, at 622.
RejeskiD, “The Next Small Thing,”The Environmental Forum, March-April 2004, at 42, 45.
45.
DaviesJ. C., Woodrow Wilson International Center for Scholars, Project on Emerging Nanotechnologies, Report, Managing the Effects of Nanotechnology (2006).
46.
Id., at 14.
47.
Id., at 10.
48.
Id., at 11.
49.
Id., at 10.
50.
Id., at 10.
51.
RennO. and RocoM., “Nanotechnology and the Need for Risk Governance,”Journal of Nanoparticle Research8, no. 2 (2006): at 1, Table 3.
OberdörsterGunter, “Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles,”Environmental Health Perspectives113 (2005): 823–839, at 823.
63.
WarheitD. B., “Comparative Pulmonary Toxicity Assessment of Single-Wall Carbon Nanotubes in Rats,”Toxicological Science77 (2004): 117–125, at 117; LamC. W., “Pulmonary Toxicity of Single-Wall Carbon Nanotubes in Mice 7 and 90 Days after Intratracheal Instillation,”Toxicological Science77 (2004): 126–134, at 126; ShvedovaA. A., “Exposure to Carbon Nanotube Material: Assessment of Nanotube Cytotoxicity Using Human Keratinocyte Cells,”Journal of Toxicology & Environmental Health66 (2003): Part A, 1909–1926, at 1909.
64.
See Lam, supra note 62.
65.
Supra note 62, at 827.
66.
Id., at 826.
67.
See National Institute for Occupational Safety and Health website, “Nanotechnology at NIOSH”at <http://www.cdc.gov/niosh/topics/nanotech/> (last visited September 14, 2006).
68.
Supra note 62, at 829.
69.
Supra note 62.
70.
Supra note 62.
71.
Supra note 62.
72.
Supra note 62, at 830–831.
73.
Supra note 62, at 829.
74.
Supra note 62, at 830.
75.
See KreylingW. G., “Translocation of Ultrafine Insoluble Iridium Particles from Lung Epithelium to Extrapulmonary Organs is Size Dependent but Very Low,”Journal of Toxicology and Environmental Health65 (2002): 1513–1530; OberdörsterG, “Volumetric Loading of Alveolar Macrophages (AM): A Possible Basis for Diminished AM-Mediated Particle Clearance,”Experimental Lung Research18 (1992): 87–104; SemmlerM., “Long-Term Clearance Kinetics of Inhaled Ultrafine Insoluble Iridium Particles from the Rat Lung, Including Transient Translocation into Secondary Organs,”Inhalation Toxicology16 (2004): 453–459.
76.
Supra note 62, at 830.
77.
Supra note 62.
78.
Supra note 62.
79.
Supra note 62.
80.
Supra note 62, at 831.
81.
TinkleS. S., “Skin as a Route of Exposure and Sensitization in Chronic Beryllium Disease,”Environmental Health Perspectives111, no. 9 (2003): 1202–1208.
82.
Supra note 62, at 834.
83.
Supra note 62. See also OberdörsterG, “Size Dependent Lymphatic Short Term Clearance of Amosite Fibers in the Lung,”Annals of Occupational Hygiene32 (1988): 149–156.
84.
Robichaud, supra note 18, at 8985.
85.
Robichaud, supra note 18, at 8985.
86.
Robichaud, supra note 18, at 8988.
87.
Robichaud, supra note 18, at 8990.
88.
Robichaud, supra note 18, at 8990.
89.
Robichaud, supra note 18, at 8990.
90.
Robichaud, supra note 18, at 8990.
91.
Robichaud, supra note 18, at 8991.
92.
MarchantG. E. and SylvesterD. J., “Transnational Models for Regulation of Nanotechnology,”Journal of Law, Medicine & Ethics34, no. 4 (2006): 714–725.
93.
Id.
94.
Id.
95.
HolmS. and HarrisJ., Letter, “Precautionary Principle Stifles Discovery,”Nature400 (July, 1999) at 398.
96.
Supra note 51, at Table 13.
97.
MacDonaldJ. W., “Commentary, Terrorism, Insurance, and TRIA: Are We Asking the Right Questions?”John Liner Review18, no. 2 (2004): at 87, 89. Available at <http://www.autoturista.com.mx/docs/JLR_Summer_2004.pdf> (last visited September 15, 2006).
Id. A second reinsurer, Allianz, believes that it is not appropriate at this time to consider a general exclusion of nanotechnology from insurance coverage because Nanotechnologies cover a very broad field with far from uniform characteristics. The terminology used in nanotechnologies is very broad. No uniform language or set of definitions exist; the sheer variety of nanotechnologies and their applications across broad sections of industrial segments mean a positive diversification effect for insurance portfolios; and the exposure of the general population to nanotechnologies is still comparatively low. Allianz website, “Small Sizes that Matter: Opportunities and Risks of Nanotechnologies” (2005): at 5, available at <http://www.allianz.com/azcom/dp/cda/0,796786-44,00.html> (last visited September 15, 2006). [hereinafter Opportunities and Risks].
100.
“Opportunities and Risks,”supra note 99, at 5.
101.
Hett, supra note 98.
102.
AbrahamKenneth S., Insurance Law & Regulation: Cases and Materials, 4th ed. (Foundation Press, 2005): at 153.
103.
Terrorism Risk and Insurance Act of 2002, Pub. L. No. 107-297. 116 Stat. 2322.
National Science Foundation, Grant Policy Manual (2005): at 117, available at <http://www.nsf.gov/publications/pub_summ.jsp?ods_key=gpm> (last visited September 15, 2006). NSF's Grant General Conditions guide also advises grantees to protect themselves as “NSF cannot assume any liability for accidents, illnesses or claims arising out of any work supported by an award or for unauthorized use of patented or copyrighted materials.” National Science Foundation, Grant General Conditions (GC-1) (2006): at 37, available at <http://www.nsf.gov/publications/pub_summ.jsp?ods_key=gc131506> (last visited September 15, 2006).
108.
Andrew Maynard, Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies, Report, Nanotechnology: A Research Strategy for Addressing Risk (July 2006).